Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8741MR)

This product GTTS-WQ8741MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8741MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10912MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ6393MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ937MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ14034MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ1752MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ8880MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ15198MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ9256MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW